The Pace of Development of Molecular Imaging Agents
Executive Summary
The adoption of new in vivo molecular imaging agents may eventually follow the current path of in vitro diagnostics, which for some products is shifting from a cost-effectiveness standard for reimbursement toward an evidence-based. But the companies most likely to support the clinical trials that would establish such benefits are only slowly integrating the development of molecular agents into their core businesses. IVD - an area of acquisition interest for these companies -may be the force that transforms them into more biologically minded and innovation-driven entities, and in so doing it may bolster the development of molecular imaging agents.
You may also be interested in...
Siemens’ Companion Dx Deals Address Pharma’s Interest In Multiple Technologies
Separate deals with Viiv Healthcare and gene therapy specialist Tocagen illustrate the increasing emphasis on application of multiple technologies toward the development of companion diagnostics, as pharma strives to determine how best to assure market access to its targeted drugs.
Market & Industry Briefs
Brief summaries of recent medtech market and industry developments. This month we cover news from the TAVI space, ConforMIS’ customized knee implants, and Siemens’ recent companion diagnostic dealmaking.
Siemens’ Companion Dx Deals Showcase Multiple Technologies, Improve Market Access
Siemens has joined the ranks of companies offering services to pharma to develop companion diagnostics, with the concurrent announcements in February of separate deals with Viiv Healthcare and gene therapy specialist Tocagen. In different ways, the transactions illustrate the increasing emphasis on application of multiple technologies toward the development of companion diagnostics, as pharma strives to determine how best to assure market access to its targeted drugs.